Cimerli Alternatives Compared
| Cimerli (ranibizumab) | Eylea (aflibercept) | Syfovre (pegcetacoplan) |
|
|---|
| Cimerli (ranibizumab) | Eylea (aflibercept) | Syfovre (pegcetacoplan) |
|
|||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Prescription only
Prescribed for Macular Edema Following Retinal Vein Occlusion , Macular Degeneration, Myopic Choroidal Neovascularization, Macular Edema, Diabetic Macular Edema, Diabetic Retinopathy. Cimerli may... View more |
Prescription only
Eylea / Eylea HD are VEGF (vascular endothelial growth factor) inhibitors that used to treat retinal eye diseases that may affect your vision, including neovascular (wet) age-related macular... View more |
Prescription only
Prescribed for Geographic Atrophy, Macular Degeneration. Syfovre may also be used for purposes not listed in this medication guide. |
Related suggestions Macular Degeneration
|
|||||||||||||||||||||||
| More about Cimerli (ranibizumab) | More about Eylea (aflibercept) | More about Syfovre (pegcetacoplan) | ||||||||||||||||||||||||
| Ratings & Reviews | ||||||||||||||||||||||||||
|
Be the first to share your experience with this drug. |
Eylea has an average rating of 7.1 out of 10 from a total of 70 ratings on Drugs.com. 66% of reviewers reported a positive effect, while 20% reported a negative effect. |
Syfovre has an average rating of 8.2 out of 10 from a total of 6 ratings on Drugs.com. 67% of reviewers reported a positive effect, while 17% reported a negative effect. |
||||||||||||||||||||||||
| Side Effects Experienced by Users Side effects are reported in Drugs.com user reviews and not clinically verified. | ||||||||||||||||||||||||||
|
View all Cimerli side effects |
View all Eylea side effects |
View all Syfovre side effects |
||||||||||||||||||||||||
| Drug Class | ||||||||||||||||||||||||||
| Generic Availability | ||||||||||||||||||||||||||
|
N/A |
N/A |
|||||||||||||||||||||||||
| Pricing and Coupons * Prices are without insurance | ||||||||||||||||||||||||||
View all Cimerli prices |
View all Eylea prices |
View all Syfovre prices |
||||||||||||||||||||||||
| Dosage Forms | ||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||
| Brand Names | ||||||||||||||||||||||||||
| Other ranibizumab brands include: Byooviz, Lucentis, Susvimo | Other aflibercept brands include: Ahzantive, Enzeevu, Eylea HD, Opuviz, Pavblu, Yesafili |
N/A |
||||||||||||||||||||||||
| Half Life Drug half-life is the time required for plasma concentration to reduce to half its original value. | ||||||||||||||||||||||||||
|
216 hours |
144 hours |
108 hours |
||||||||||||||||||||||||
| CSA Schedule 1 View glossary of CSA terms | ||||||||||||||||||||||||||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||||||||||
| Pregnancy Category | ||||||||||||||||||||||||||
|
Category C
Risk cannot be ruled out
See the full pregnancy warnings document. |
Category C
Risk cannot be ruled out
See the full pregnancy warnings document. |
Summary unavailable. See the full pregnancy warnings document. |
||||||||||||||||||||||||
| Drug Interactions | ||||||||||||||||||||||||||
|
A total of 1 drugs are known to interact with Cimerli:
|
No known drug interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
A total of 2 drugs are known to interact with Syfovre:
|
||||||||||||||||||||||||
| Alcohol/Food/Lifestyle Interactions | ||||||||||||||||||||||||||
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
||||||||||||||||||||||||
| Disease Interactions | ||||||||||||||||||||||||||
|
No known disease interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
||||||||||||||||||||||||||
| First Approval Date | ||||||||||||||||||||||||||
|
N/A |
November 18, 2011 |
N/A |
||||||||||||||||||||||||
| WADA Class View classifications | ||||||||||||||||||||||||||
|
N/A |
N/A |
N/A |
||||||||||||||||||||||||
| More Information | ||||||||||||||||||||||||||
| Patient Resources | ||||||||||||||||||||||||||
| Professional Resources | ||||||||||||||||||||||||||
| Related Treatment Guide | ||||||||||||||||||||||||||
1 The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.